Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel F Hanley

Showing results (221-230 of 267) with videos related to

Pageof 27
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 1, 2024
Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasmaQuigly Dragotakes, Patrick W Johnson, Matthew R Buras, et al.
The New England Journal of Medicine|September 17, 2025
A Randomized Trial of Shunting for Idiopathic Normal-Pressure HydrocephalusMark G Luciano, Michael A Williams, Mark G Hamilton, et al.
Journal of Clinical and Translational Science|January 17, 2024
The Trial Innovation Network Liaison Team: building a national clinical and translational community of practiceMarisha E Palm, Dixie D Thompson, Terri Edwards, et al.
Expert Review of Anti-Infective Therapy|January 27, 2026
COVID-19 convalescent plasma safety and efficacy analysis for biologics license application approvalDavid J Sullivan, Rita Reik, Alicia Prichard, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of atorvastatin for rebleeding in cerebral cavernous malformations (AT CASH EPOC): a phase 1/2a, randomised placebo-controlled trialIssam A Awad, Roberto J Alcazar-Felix, Agnieszka Stadnik, et al.
Journal of Clinical and Translational Science|January 17, 2024
Development, implementation, and dissemination of operational innovations across the trial innovation networkMarisha E Palm, Terri L Edwards, Cortney Wieber, et al.
Neurology|December 23, 2021
Cerebral Microbleeds and Acute Hematoma Characteristics in the ATACH-2 and MISTIE III TrialsJessica R Magid-Bernstein, Yunke Li, Sung-Min Cho, et al.
Neurosurgery|March 21, 2019
Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) ProcedureIssam A Awad, Sean P Polster, Julián Carrión-Penagos, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|April 5, 2019
A randomized 500-subject open-label phase 3 clinical trial of minimally invasive surgery plus alteplase in intracerebral hemorrhage evacuation (MISTIE III)Wendy C Ziai, Nichol McBee, Karen Lane, et al.
Stroke|August 6, 2015
Accuracy of the ABC/2 Score for Intracerebral Hemorrhage: Systematic Review and Analysis of MISTIE, CLEAR-IVH, and CLEAR IIIAlastair J S Webb, Natalie L Ullman, Tim C Morgan, et al.
Pageof 27

Showing results (221-230 of 267) with videos related to

Sort By:
Pageof 27
Proceedings of the National Academy of Sciences of the United States of America|October 1, 2024
Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasmaQuigly Dragotakes, Patrick W Johnson, Matthew R Buras, et al.
The New England Journal of Medicine|September 17, 2025
A Randomized Trial of Shunting for Idiopathic Normal-Pressure HydrocephalusMark G Luciano, Michael A Williams, Mark G Hamilton, et al.
Journal of Clinical and Translational Science|January 17, 2024
The Trial Innovation Network Liaison Team: building a national clinical and translational community of practiceMarisha E Palm, Dixie D Thompson, Terri Edwards, et al.
Expert Review of Anti-Infective Therapy|January 27, 2026
COVID-19 convalescent plasma safety and efficacy analysis for biologics license application approvalDavid J Sullivan, Rita Reik, Alicia Prichard, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of atorvastatin for rebleeding in cerebral cavernous malformations (AT CASH EPOC): a phase 1/2a, randomised placebo-controlled trialIssam A Awad, Roberto J Alcazar-Felix, Agnieszka Stadnik, et al.
Journal of Clinical and Translational Science|January 17, 2024
Development, implementation, and dissemination of operational innovations across the trial innovation networkMarisha E Palm, Terri L Edwards, Cortney Wieber, et al.
Neurology|December 23, 2021
Cerebral Microbleeds and Acute Hematoma Characteristics in the ATACH-2 and MISTIE III TrialsJessica R Magid-Bernstein, Yunke Li, Sung-Min Cho, et al.
Neurosurgery|March 21, 2019
Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) ProcedureIssam A Awad, Sean P Polster, Julián Carrión-Penagos, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|April 5, 2019
A randomized 500-subject open-label phase 3 clinical trial of minimally invasive surgery plus alteplase in intracerebral hemorrhage evacuation (MISTIE III)Wendy C Ziai, Nichol McBee, Karen Lane, et al.
Stroke|August 6, 2015
Accuracy of the ABC/2 Score for Intracerebral Hemorrhage: Systematic Review and Analysis of MISTIE, CLEAR-IVH, and CLEAR IIIAlastair J S Webb, Natalie L Ullman, Tim C Morgan, et al.
Pageof 27